AGEN US00847G7051

Report

Delayed Nasdaq - 05/18 04:00:00 pm
1.53	USD		-7.27%

05/12	TARGOVAX ASA : First quarter 2022 results	AQ
05/11	Targovax announces clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 melanoma trial	AQ
05/11	Targovax Announces Clinical Collaboration with Agenus for Upcoming ONCOS-102 Phase 2 Melanoma Trial	CI

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

05/12/2022	05/13/2022	05/16/2022	05/17/2022	05/18/2022	Date
1.55(c)	1.63(c)	1.58(c)	1.65(c)	1.53	Last
8 933 573	5 179 160	3 653 681	5 301 641	4 431 692	Volume
+2.65%	+5.16%	-3.07%	+4.43%	-7.27%	Change

More quotes

Estimated financial data (e) (USD)

Sales 2022	62,2 M - -
Net income 2022	-238 M - -
Net Debt 2022	- - -
P/E ratio 2022	-1,71x
Yield 2022	-

Sales 2023	95,8 M - -
Net income 2023	-235 M - -
Net Debt 2023	- - -
P/E ratio 2023	-2,01x
Yield 2023	-

Capitalization	415 M 415 M -
Capi. / Sales 2022	6,67x
Capi. / Sales 2023	4,33x
Nbr of Employees	441
Free-Float	89,9%

More Financials

Company

Agenus Inc. is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4...

Sector

Biotechnology & Medical Research

Calendar

08/11

Earnings Release

More about the company

Ratings of Agenus Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

All news about AGENUS INC.

05/12	TARGOVAX ASA : First quarter 2022 results	AQ
05/11	Targovax announces clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 me..	AQ
05/11	Targovax Announces Clinical Collaboration with Agenus for Upcoming ONCOS-102 Phase 2 Me..	CI
05/11	Blow to Roche's cancer immunotherapy prospects as 2nd trial fails	RE
05/10	TRANSCRIPT : Agenus Inc., Q1 2022 Earnings Call, May 10, 2022	CI
05/10	AGENUS : Q1 Earnings Snapshot	AQ
05/10	Agenus Corporate Update and First Quarter 2022 Financial Report	GL
05/10	Agenus Corporate Update and First Quarter 2022 Financial Report	AQ
05/10	AGENUS INC Management's Discussion and Analysis of Financial Condition and Results ..	AQ
05/10	Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
05/10	Targovax and Oslo University Hospital announce collaboration to test TG mutant RAS vacc..	AQ
04/26	Agenus to Provide Corporate Update and First Quarter 2022 Financial Report	GL
04/26	Agenus to Provide Corporate Update and First Quarter 2022 Financial Report	GL
04/08	AGENUS : AACR2022_Udartseva, et al. Poster	PU
04/08	Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance	GL

More news

News in other languages on AGENUS INC.

05/11	L'efficacité du médicament anticancéreux de Roche remise en question
05/11	Targovax annonce une collaboration clinique avec Agenus pour le prochain essai de phase..
05/11	Aussicht auf neue Roche-Lungenkrebstherapie schwindet
05/10	Agenus Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/08	Agenus Inc. Présente des données sur l'AGEN1571 (anti-ILT2) à l'AACR et annonce l'appro..

More news

Analyst Recommendations on AGENUS INC.

03/03	B. Riley Lowers Agenus' Price Target to $8 from $11, Keeps Buy Rating	MT
03/02	HC Wainwright Adjusts Agenus' Price Target to $14 from $12, Reiterates Buy Rating	MT
2021	HC Wainwright Starts Agenus at Buy With $12 Price Target	MT

More recommendations

Provided by Scoopnest.com

Analysis

Bristol-Myers, Eisai in up to $3.1 billion deal to develop cancer drug candidate